EVOQ Therapeutics, an Ann Arbor, CA-based biopharmaceutical company providing disease-specific immune modulators, received a $2M grant from National Institutes of Health (NIH).
The company intends to use the amount to advance novel therapies for autoimmune diseases.
Led by CEO Dr. David Giljohann, and CSO Dr. James Moon, EVOQ Therapeutics is advancing a pipeline of disease-specific immune modulators to treat patients afflicted with autoimmune diseases. Its technology platform utilizes a proprietary NanoDisc that has been optimized to deliver antigens to restore immune tolerance.
In addition to MOG antibody disease, EVOQ therapies are also in development to treat patients with Type 1 diabetes, Celiac disease, Rheumatoid arthritis, Lupus and other chronic autoimmune diseases.
The company was launched with the assistance of Innovation Partnerships at the University of Michigan.
FinSMEs
29/08/2024